Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia
Search for other papers by A Smetanka in
Current site
Google Scholar
PubMed
Search for other papers by V Stara in
Current site
Google Scholar
PubMed
Search for other papers by I Farsky in
Current site
Google Scholar
PubMed
Search for other papers by I Tonhajzerova in
Current site
Google Scholar
PubMed
Search for other papers by I Ondrejka in
Current site
Google Scholar
PubMed
Introduction
Major depressive disorder is a serious mental disorder in which treatment with antidepressant medication is associated with incidence of adverse events, such as constipation, diarrhea, dry mouth, headache, insomnia, and sexual dysfunction (SDys). Escitalopram (ESC), an effective and safe selective serotonin reuptake inhibitor with good tolerability, was used in this study. In this study, we investigated the prospective effect of Pycnogenol (PYC), an antioxidant, anti-inflammatory, and vasodilator agent, on ESC-induced SDys.
Methods
This was a randomized, parallel, open-label study. Seventy-two outpatients of both genders with depression were randomized into two groups as follows: 37 patients from the ESC + PYC group took 50 mg of PYC per day for 4 months in ESC co-treatment, and 35 subjects from the ESC group took ESC only. Five patients dropped out and were excluded from the analysis. The participants were examined every month (visits 1–4).
Results
ESC use led to improvement of depressive symptoms and severity scored by standardized psychiatric tests. PYC co-treatment resulted in attenuation of SDys beginning at 1 month of treatment and continuing for two consecutive months. Furthermore, an increase in heart rate in the PYC group was registered.
Conclusions
We propose that PYC-mediated SDys attenuation is based on its ability to improve endothelial functions by its antioxidant, anti-inflammatory, vasodilatory, and anticoagulant action. We assume that the action of PYC on heart rate is in accordance with the aforementioned vasodilatory action of PYC and consequent baroreflex-mediated heart rate response. PYC co-treatment reduced ESC-induced SDys and elevated heart rate.
-
1.
Aoki H , Nagao J , Ueda T , Strong JM , Schonlau F , Yu-Jing S , Lu Y , Horie S : Clinical assessment of a supplement of Pycnogenol® and L-arginine in Japanese patients with mild to moderate erectile dysfunction. Phytother. Res. 26, 204–207 (2012)
-
2.
Araghi-Niknam M , Hosseini S , Larson D , Rohdewald P , Watson RR : Pine bark extract reduces platelet aggregation. Integr. Med. 2, 73–77 (2000)
-
3.
Ashton AK , Jamerson BD , L. Weinstein W , Wagoner C : Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr. Ther. Res. 66, 96–106 (2005)
-
4.
Bauer M , Monz BU , Montejo AL , Quail D , Dantchev N , Demyttenaere K , Garcia-Cebrian A , Grassi L , Perahia DG , Reed C , Tylee A : Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur. Psychiatry 23, 66–73 (2008)
-
5.
Belmaker RH , Agam G : Major depressive disorder. N. Engl. J. Med. 358, 55–68 (2008)
-
6.
Cates M : Selecting antidepressant therapy for patients with major depression. Am. J. Pharm. Educ. 65, 190–194 (2001)
-
7.
Cesarone MR , Belcaro G , Rohdewald P , Pellegrini L , Ledda A , Vinciguerra G , Ricci A , Ippolito E , Fano F , Dugall M , Cacchio M , Di Renzo A , Hosoi M , Stuard S , Corsi M : Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol®: a prospective, controlled study. Phytomedicine 17, 835–839 (2010)
-
8.
Clayton A , Kornstein S , Prakash A , Mallinckrodt C , Wohlreich M : Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J. Sex. Med. 4, 917–929 (2007)
-
9.
Corona G , Ricca V , Bandini E , Mannucci E , Lotti F , Boddi V , Rastrelli G , Sforza A , Faravelli C , Forti G , Maggi M : Selective serotonin reuptake inhibitor-induced sexual dysfunction. J. Sex. Med. 6, 1259–1269 (2009)
-
10.
D’Andrea G : Pycnogenol: a blend of procyanidins with multifaceted therapeutic applications? Fitoterapia 81, 724–736 (2010)
-
11.
Drieling RL , Gardner CD , Ma J , Ahn DK , Stafford RS : No beneficial effects of pine bark extract on cardiovascular disease risk factors. Arch. Intern. Med. 170, 1541–1547 (2010)
-
12.
D̆uračková Z , Trebatický B , Novotný V , Žitňanová I , Breza J : Lipid metabolism and erectile function improvement by pycnogenol®, extract from the bark of Pinus pinaster in patients suffering from erectile dysfunction – a pilot study. Nutr. Res. 23, 1189–1198 (2003)
-
13.
Enseleit F , Sudano I , Periat D , Winnik S , Wolfrum M , Flammer AJ , Fröhlich GM , Kaiser P , Hirt A , Haile SR , Krasniqi N , Matter CM , Uhlenhut K , Högger P : Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. Eur. Heart J. 33, 1589–1597 (2012)
-
14.
Ferguson JM : SSRI antidepressant medications: adverse effects and tolerability. Prim. Care Companion J. Clin. Psychiatry 3, 22–27 (2001)
-
15.
Grimm T , Chovanová Z , Muchová J , Sumegová K , Liptáková A , Duracková Z , Högger P : Inhibition of NF-κB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J. Inflamm. (Lond.) 3, 1 (2006)
-
16.
Grimm T , Skrabala R , Chovanová Z , Muchová J , Sumegová K , Liptáková A , Durackova Z , Högger P : Single and multiple dose pharmacokinetics of maritime pine bark extract (Pycnogenol) after oral administration to healthy volunteers. BMC Clin. Pharmacol. 6, 4 (2006)
-
17.
Hatzimouratidis K , Amar E , Eardley I , Giuliano F , Hatzichristou D , Montorsi F , Vardi Y , Wespes E , European Association of Urology : Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur. Urol. 57, 804–814 (2010)
-
18.
Hausenblas HA , Saha D , Dubyak PJ , Anton SD : Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J. Integr. Med. 11, 377–383 (2013)
-
19.
Higgins A , Nash M , Lynch AM : Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc. Patient Saf. 2, 141–150 (2010)
-
20.
Hosseini S , Lee J , Sepulveda RT , Rohdewald P , Watson RR : A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr. Res. 21, 1251–1260 (2001)
-
21.
Jankyova S , Hlavackova L , Kralova E , Slazneva J , Drobna V , Zuzik P , Drafi F , Mucaji P , Racanska E : The evaluation of efficacy of Pycnogenol® fractions on endothelial dysfunction. Acta Fac. Pharm. Univ. Comen. 60, 7–14 (2013)
-
22.
Kennedy SH , Andersen HF , Lam RW : Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J. Psychiatry Neurosci. 31, 122–131 (2006)
-
23.
Kennedy SH , Lam RW , McIntyre RS , Tourjman SV , Bhat V , Blier P , Hasnain M , Jollant F , Levitt AJ , MacQueen GM , McInerney SJ , McIntosh D , Milev RV , Müller DJ , Parikh SV , Pearson NL , Ravindran AV , Uher R , CANMAT Depression Work Group: Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Can. J. Psychiatry 61, 540–560 (2016)
-
24.
Kobori Y , Suzuki K , Iwahata T , Shin T , Sadaoka Y , Sato R , Nishio K , Yagi H , Arai G , Soh S , Okada H , Strong JM , Rohdewald P : Improvement of seminal quality and sexual function of men with oligoasthenoteratozoospermia syndrome following supplementation with L-arginine and Pycnogenol®. Arch. Ital. Urol. Androl. 87, 190–193 (2015)
-
25.
Lamm S , Schönlau F , Rohdewald P : Prelox® for improvement of erectile function: a review. Eur. Bull. Drug Res. 11, 29–37 (2003)
-
26.
Ledda A , Belcaro G , Cesarone MR , Dugall M , Schönlau F : Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. BJU Int. 106, 1030–1033 (2010)
-
27.
Lewer D , O’Reilly C , Mojtabai R , Evans-Lacko S : Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. Br. J. Psychiatry 207, 221–226 (2015)
-
28.
Liu X , Wei J , Tan F , Zhou S , Würthwein G , Rohdewald P : Antidiabetic effect of Pycnogenol® French maritime pine bark extract in patients with diabetes type II. Life Sci. 75, 2505–2513 (2004)
-
29.
Montgomery SA , Asberg M : A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382–389 (1979)
-
30.
Mullen W , Edwards CA , Crozier A : Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br. J. Nutr. 96, 107–116 (2006)
-
31.
Mülek M , Seefried L , Genest F , Högger P : Distribution of constituents and metabolites of maritime pine bark extract (Pycnogenol®) into serum, blood cells, and synovial fluid of patients with severe osteoarthritis: a randomized controlled trial. Nutrients 9, 443 (2017)
-
32.
Müller MJ , Himmerich H , Kienzle B , Szegedi A : Differentiating moderate and severe depression using the Montgomery–Åsberg Depression Rating Scale (MADRS). J. Affect. Disord. 77, 255–260 (2003)
-
33.
Nishioka K , Hidaka T , Nakamura S , Umemura T , Jitsuiki D , Soga J , Goto C , Chayama K , Yoshizumi M , Higashi Y : Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens. Res. 30, 775–780 (2007)
-
34.
Nocun M , Ulicna O , Muchova J , Durackova Z , Watala C : French maritime pine bark extract (Pycnogenol®) reduces thromboxane generation in blood from diabetic male rats. Biomed. Pharmacother. 62, 168–172 (2008)
-
35.
Pandey KB , Rizvi SI : Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell Longev. 2, 270–278 (2009)
-
36.
Park Y-M : Serum prolactin levels in patients with major depressive disorder receiving selective serotonin-reuptake inhibitor monotherapy for 3 months: a prospective study. Psychiatry Investig. 14, 368–371 (2017)
-
37.
Perry AG , Potter PA , Ostendorf W (2014): Clinical Nursing Skills and Techniques (8th ed.). Mosby, St. Louis, MO
-
38.
Schäfer A , Chovanová Z , Muchová J , Sumegová K , Liptáková A , Durackova Z , Högger P : Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed. Pharmacother. 60, 5–9 (2006)
-
39.
Schönthal AH : Adverse effects of concentrated green tea extracts. Mol. Nutr. Food Res. 55, 874–885 (2011)
-
40.
Siasos G , Tousoulis D , Antoniades C , Stefanadi E , Stefanadis C : L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? Int. J. Cardiol. 116, 300–308 (2007)
-
41.
Sivonová M , Waczulíková I , Kilanczyk E , Hrnciarová M , Bryszewska M , Klajnert B , Durackova Z : The effect of Pycnogenol on the erythrocyte membrane fluidity. Gen. Physiol. Biophys. 23, 39–51 (2004)
-
42.
Stanislavov R , Nikolova V : Treatment of erectile dysfunction with pycnogenol and L-arginine. J. Sex. Marital. Ther. 29, 207–213 (2003)
-
43.
Stanislavov R , Nikolova V , Rohdewald P : Improvement of erectile function with Prelox: a randomized, double-blind, placebo-controlled, crossover trial. Int. J. Impot. Res. 20, 173–180 (2008)
-
44.
Taner G , Aydın S , Aytaç Z , Başaran AA , Başaran N : Assessment of the cytotoxic, genotoxic, and antigenotoxic potential of Pycnogenol® in in vitro mammalian cells. Food Chem. Toxicol. 61, 203–208 (2013)
-
45.
Yagi H , Sato R , Nishio K , Arai G , Soh S , Okada H : Effects of a supplement combining Pycnogenol® and L-arginine aspartate on lower urinary dysfunction compared with saw palmetto extract. J. Tradit. Complement. Med. 7, 117–120 (2017)
Editor-in-Chief
László ROSIVALL (Semmelweis University, Budapest, Hungary)
Managing Editor
Anna BERHIDI (Semmelweis University, Budapest, Hungary)
Co-Editors
- Gábor SZÉNÁSI (Semmelweis University, Budapest, Hungary)
- Ákos KOLLER (Semmelweis University, Budapest, Hungary)
- Zsolt RADÁK (University of Physical Education, Budapest, Hungary)
- László LÉNÁRD (University of Pécs, Hungary)
- Zoltán UNGVÁRI (Semmelweis University, Budapest, Hungary)
Assistant Editors
- Gabriella DÖRNYEI (Semmelweis University, Budapest, Hungary)
- Zsuzsanna MIKLÓS (Semmelweis University, Budapest, Hungary)
- György NÁDASY (Semmelweis University, Budapest, Hungary)
Hungarian Editorial Board
- György BENEDEK (University of Szeged, Hungary)
- Zoltán BENYÓ (Semmelweis University, Budapest, Hungary)
- Mihály BOROS (University of Szeged, Hungary)
- László CSERNOCH (University of Debrecen, Hungary)
- Magdolna DANK (Semmelweis University, Budapest, Hungary)
- László DÉTÁRI (Eötvös Loránd University, Budapest, Hungary)
- Zoltán GIRICZ (Semmelweis University, Budapest, Hungary and Pharmahungary Group, Szeged, Hungary)
- Zoltán HANTOS (Semmelweis University, Budapest and University of Szeged, Hungary)
- Zoltán HEROLD (Semmelweis University, Budapest, Hungary)
- László HUNYADI (Semmelweis University, Budapest, Hungary)
- Gábor JANCSÓ (University of Pécs, Hungary)
- Zoltán KARÁDI (University of Pecs, Hungary)
- Miklós PALKOVITS (Semmelweis University, Budapest, Hungary)
- Gyula PAPP (University of Szeged, Hungary)
- Gábor PAVLIK (University of Physical Education, Budapest, Hungary)
- András SPÄT (Semmelweis University, Budapest, Hungary)
- Gyula SZABÓ (University of Szeged, Hungary)
- Zoltán SZELÉNYI (University of Pécs, Hungary)
- Lajos SZOLLÁR (Semmelweis University, Budapest, Hungary)
- József TOLDI (MTA-SZTE Neuroscience Research Group and University of Szeged, Hungary)
- Árpád TÓSAKI (University of Debrecen, Hungary)
International Editorial Board
- Dragan DJURIC (University of Belgrade, Serbia)
- Christopher H. FRY (University of Bristol, UK)
- Stephen E. GREENWALD (Blizard Institute, Barts and Queen Mary University of London, UK)
- Tibor HORTOBÁGYI (University of Groningen, Netherlands)
- George KUNOS (National Institutes of Health, Bethesda, USA)
- Massoud MAHMOUDIAN (Iran University of Medical Sciences, Tehran, Iran)
- Tadaaki MANO (Gifu University of Medical Science, Japan)
- Luis Gabriel NAVAR (Tulane University School of Medicine, New Orleans, USA)
- Hitoo NISHINO (Nagoya City University, Japan)
- Ole H. PETERSEN (Cardiff University, UK)
- Ulrich POHL (German Centre for Cardiovascular Research and Ludwig-Maximilians-University, Planegg, Germany)
- Andrej A. ROMANOVSKY (University of Arizona, USA)
- Anwar Ali SIDDIQUI (Aga Khan University, Karachi, Pakistan)
- Csaba SZABÓ (University of Fribourg, Switzerland)
- Eric VICAUT (Université de Paris, UMRS 942 INSERM, France)
Editorial Correspondence:
Physiology International
Semmelweis University
Faculty of Medicine, Institute of Translational Medicine
Nagyvárad tér 4, H-1089 Budapest, Hungary
Phone/Fax: +36-1-2100-100
E-mail: pi@semmelweis.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- EMBASE/Excerpta Medica
- Global Health
- Index Copernicus
- Index Medicus
- Medline
- Referativnyi Zhurnal
- SCOPUS
- WoS - Science Citation Index Expanded
| 2023 | |
|---|---|
| Web of Science | |
| Journal Impact Factor | 2.2 |
| Rank by Impact Factor | Q3 (Physiology) |
| Journal Citation Indicator | 0.58 |
| Scopus | |
| CiteScore | 3.4 |
| CiteScore rank | Q2 (Physical Therapy, Sports Therapy and Rehabilitation) |
| SNIP | 0.508 |
| Scimago | |
| SJR index | 0.407 |
| SJR Q rank | Q2 |
| Physiology International | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article |
| Printed Color Illustrations | 40 EUR (or 10 000 HUF) + VAT / piece |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2025 | Online subsscription: 752 EUR / 828 USD Print + online subscription: 880 EUR / 968 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Physiology International | |
|---|---|
| Language | English |
| Size | B5 |
| Year of Foundation |
2006 (1950) |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 2498-602X (Print) |
| ISSN | 2677-0164 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Apr 2024 | 104 | 0 | 0 |
| May 2024 | 78 | 0 | 0 |
| Jun 2024 | 117 | 1 | 2 |
| Jul 2024 | 47 | 0 | 0 |
| Aug 2024 | 114 | 0 | 0 |
| Sep 2024 | 117 | 0 | 0 |
| Oct 2024 | 39 | 0 | 0 |
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.